Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04720183 · ClinicalTrials.gov registry record · Phase 1
Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects
A Phase 1 study of Healthy, sponsored by Galapagos.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT04720183: Completed Phase 1 study of Healthy, sponsored by Galapagos.
NCT04720183 is a Phase 1 study of Healthy that has completed, run by Galapagos. The registered enrollment target is 8 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04720183, a Phase 1 study of Healthy, has completed, sponsored by Galapagos.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
GLPG3970 will be given with sulfasalazine to investigate the effect of co-administration on the pharmacokinetics of sulfasalazine, and on the safety and tolerability of the drugs in healthy adult subjects.
Conditions Studied
Interventions
- DRUG Sulfasalazine
- DRUG GLPG3970
Study Locations (1)
New Jersey
- Biotral Inc - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-01-11 |
| Est. Completion | 2021-04-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04720183
The ClinicalTrials.gov registry entry for NCT04720183 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (99% lower). The listed sponsor is Galapagos, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Sulfasalazine is the first listed.
NCT04720183 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT04720183 about?
NCT04720183 is a clinical study titled "Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects". GLPG3970 will be given with sulfasalazine to investigate the effect of co-administration on the pharmacokinetics of sulfasalazine, and on the safety and tolerability of the drugs in healthy adult subjects.
What is the current status of trial NCT04720183?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-01-11. Estimated completion is 2021-04-23.
What conditions does trial NCT04720183 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT04720183?
The interventions under investigation include: Sulfasalazine (DRUG), GLPG3970 (DRUG).
Who is sponsoring clinical trial NCT04720183?
This trial is sponsored by Galapagos, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04720183 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.